Table of Contents PART 01: Executive summary PART 02: Scope of  the report PART 03: Research Methodology PART 04: Introduction Key market highlights PART 05: Key pipeline PART 06: Market landscape Market overview Market size and forecast Five forces analysis PART 07: High burden countries (HBCs) Categorization of HBCs PART 08: TB diagnostics Overview PART 09: Market segmentation by disease type Global latent TB market Global active TB market PART 10: Market segmentation by drug class Global first-line anti-TB drugs market Global second-line anti-TB drugs market PART 11: Geographical segmentation TB drugs market in Americas TB drugs market in EMEA TB drug market in APAC PART 12: Market drivers Increase in outbreak of TB-HIV co-infections Emergence of MDR-TB and XDR-TB strains Increasing incidence of TB in Africa and Asia PART 13: Impact of drivers PART 14: Market challenges Insufficient demand and high drug cost in developed countries Liberal regulations and lack of awareness in developing countries Limited diagnostic procedures PART 15: Impact of drivers and challenges PART 16: Market trends Increased spending on TB diagnostic kits Focus on development of shorter TB drug regimens Increased focus on TB vaccine development PART 17: Vendor landscape Competitive scenario Key news PART 18: Key vendor analysis Lupin Otsuka Novel Products Pfizer Sandoz Sanofi Other prominent vendors PART 19: Appendix List of abbreviations PART 20: Explore Technavio List of Exhibits Exhibit 01: Pipeline analysis Exhibit 02: Key clinical trials Exhibit 03: Global TB drugs market snapshot Exhibit 04: Global TB drugs market 2016-2021 ($ millions) Exhibit 05: Opportunity analysis in global TB drugs market Exhibit 06: Five forces analysis Exhibit 07: List of major HBCs Exhibit 08: Advanced technologies used for TB diagnostics Exhibit 09: Tests recommended for diagnosis of active TB Exhibit 10: Drugs used as first-line anti-TB agents Exhibit 11: Global first-line anti-TB drugs market 2016-2021 ($ millions) Exhibit 12: Drugs used as second-line anti-TB agents Exhibit 13: Global second-line anti-TB drugs market 2016-2021 ($ millions) Exhibit 14: TB drugs market scenario in Americas Exhibit 15: TB drugs market in Americas 2016-2021 ($ millions) Exhibit 16: Number of TB cases reported in US 2010-2015 Exhibit 17: TB drugs market scenario in EMEA Exhibit 18: TB drugs market in EMEA 2016-2021 ($ millions) Exhibit 19: TB drugs market scenario in APAC Exhibit 20: TB drugs market in APAC 2016-2021 ($ millions) Exhibit 21: Impact of drivers Exhibit 22: Impact of drivers and challenges Exhibit 23: Testing process in BCG vaccines Exhibit 24: Competitive structure analysis of global TB drug market 2016 Exhibit 25: Lupin: Key highlights Exhibit 26: Lupin: Strength assessment Exhibit 27: Lupin: Strategy assessment Exhibit 28: Lupin: Opportunity assessment Exhibit 29: Otsuka Novel Products: Key highlights Exhibit 30: Otsuka Novel Products: Strength assessment Exhibit 31: Otsuka Novel Products: Strategy assessment Exhibit 32: Pfizer: Key highlights Exhibit 33: Pfizer: Strength assessment Exhibit 34: Pfizer: Strategy assessment Exhibit 35: Pfizer: Opportunity assessment Exhibit 36: Sandoz: Key highlights Exhibit 37: Sandoz: Strength assessment Exhibit 38: Sandoz: Strategy assessment Exhibit 39: Sandoz: Opportunity assessment Exhibit 40: Sanofi: Key highlights Exhibit 41: Sanofi: Strength assessment Exhibit 42: Sanofi: Strategy assessment Exhibit 43: Sanofi: Opportunity assessment

Lupin, Otsuka Novel Products, Pfizer, Sandoz, Sanofi, AstraZeneca, Archivel Farma, bioMérieux, Cepheid, EIKEN CHEMICAL, Epistem.